Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Myeloproliferative neoplasms (PV, ET, myelofibrosis), drawn from the whole corpus: 46 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No disease-modifying therapy in myelofibrosis short of transplant.
MPN in blast phase: outcomes as poor as secondary AML.
Whether interferon-induced molecular response prevents progression.
Sequencing and combining JAK inhibitors with BET, BCL-XL or CALR-directed agents.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 27 changes by month →When this page itself was last checked or edited.
Erythrocytosis in adults with polycythaemia vera
VERIFY: hepcidin mimetic controls erythrocytosis without phlebotomy; FDA approval August 2026.
Response (no phlebotomy eligibility) weeks 20 to 32: 77% vs 33%.
Pelabresib plus ruxolitinib roughly doubled the week-24 spleen volume response over ruxolitinib alone; the symptom endpoint did not reach significance.
Momelotinib improved symptom response, transfusion independence and spleen response compared with danazol; approved in September 2023.